Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTREBIS vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUTREBIS (fixed-dose combination of dapagliflozin and exenatide) combines a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist. Dapagliflozin inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Exenatide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reducing risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease (dapagliflozin component),Reducing risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors (dapagliflozin component)
Hypertension
Dutasteride 0.5 mg orally once daily.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal half-life of 8–10 hours in healthy adults, extended to 12–15 hours in moderate renal impairment (Cr Cl 30–59 m L/min); requires dose adjustment in severe renal impairment.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Dapagliflozin is primarily metabolized via uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) to an inactive metabolite. Exenatide is degraded by proteolytic degradation and eliminated via glomerular filtration with subsequent tubular reabsorption and metabolic catabolism.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Approximately 70% renal (mostly as unchanged drug via glomerular filtration and active tubular secretion), 20% fecal (via biliary excretion), and 10% metabolized with metabolites excreted equally.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
99% bound to albumin and alpha-1-acid glycoprotein.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Vd 12–15 L/kg, indicating extensive extravascular distribution and high tissue binding (primarily to erythrocytes and vascular smooth muscle).
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 45% (range 30–60%), due to incomplete absorption and first-pass metabolism. Food decreases rate but not extent.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No dose adjustment required for renal impairment. Dutasteride is not significantly renally eliminated.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment guidelines available.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not indicated in pediatric patients (<18 years). No established dosing.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
No specific dose adjustment required based on age alone. Monitor for adverse effects, particularly dizziness and hypotension, in elderly patients.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
Pancreatitis: Acute pancreatitis has been reported; discontinue if suspected,Diabetic ketoacidosis: SGLT2 inhibitors can cause ketoacidosis even with normal blood glucose levels,Volume depletion: May cause intravascular volume contraction and hypotension,Acute kidney injury: Monitor renal function,Hypoglycemia: Increased risk when used with insulin or insulin secretagogues,Severe gastrointestinal disease: Exenatide is not recommended in patients with severe gastrointestinal disease,Immunogenicity: Antibody formation to exenatide may occur
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
History of hypersensitivity to dapagliflozin, exenatide, or any excipients,Severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease (dapagliflozin component),Personal or family history of medullary thyroid carcinoma (exenatide component, based on animal studies),Patients with multiple endocrine neoplasia syndrome type 2 (exenatide component)
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Take with food to reduce tamsulosin absorption variability and decrease dizziness risk. Avoid grapefruit juice as it may increase tamsulosin levels via CYP3A4 inhibition. No other specific dietary restrictions.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
DUTREBIS (dutasteride and tamsulosin) is contraindicated in pregnancy. Dutasteride is a potent inhibitor of 5α-reductase, which can inhibit the conversion of testosterone to dihydrotestosterone (DHT). In animal studies, dutasteride caused feminization of male fetuses and impaired reproductive development. The risk is highest during the first trimester when sexual differentiation occurs. Tamsulosin, an alpha-1 adrenergic antagonist, is associated with fetal hypotension and hypoxia. No human data exist; both drugs should be avoided in pregnancy.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
DUTREBIS is contraindicated in breastfeeding. Dutasteride is excreted in human milk in animal studies; tamsulosin is excreted in rat milk. M/P ratio is unknown. Both drugs may cause adverse effects in the nursing infant, including hypotension and hormonal disruption.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
DUTREBIS is contraindicated in pregnancy and should not be used. No dose adjustments are applicable. Decreased drug clearance in pregnancy may theoretically increase exposure, but no data are available.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
DUTREBIS (dutasteride and tamsulosin) is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5-alpha-reductase inhibitor that reduces DHT levels, requiring 6 months for maximal effect. Tamsulosin is an alpha-1 blocker that provides rapid symptom relief within 2-4 weeks. Monitor for orthostatic hypotension, especially in elderly; titrate tamsulosin dose if needed. Check PSA levels before and during therapy; dutasteride reduces PSA by ~50%. Avoid in women, children, and patients with history of prostate cancer. Use with caution with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased tamsulosin exposure.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take the capsule 30 minutes after the same meal each day, preferably breakfast.,Do not crush, chew, or open the capsule; swallow whole.,Frequent ejaculation may reduce risk of retrograde ejaculation; inform if this occurs.,Rise slowly from lying or sitting to avoid dizziness or fainting.,Use effective contraception if partner is pregnant or may become pregnant; decomtamination in semen.,Report any breast lump, pain, or nipple discharge immediately.,Avoid driving until you know how the medication affects you; may cause dizziness.,Do not take with other alpha-blockers for prostate or blood pressure without doctor approval.,PSA levels will be reduced by half; inform your doctor of this effect.,Long-term treatment (6+ months) needed for maximal benefit on urinary symptoms.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTREBIS vs ALDOCLOR-150, answered by our medical review team.
DUTREBIS is a Antihypertensive Combination that works by DUTREBIS (fixed-dose combination of dapagliflozin and exenatide) combines a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist. Dapagliflozin inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Exenatide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTREBIS and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTREBIS is: Dutasteride 0.5 mg orally once daily.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTREBIS and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTREBIS is classified as Category C. DUTREBIS (dutasteride and tamsulosin) is contraindicated in pregnancy. Dutasteride is a potent inhibitor of 5α-reductase, which can inhibit the conversion of testosterone to dihydr. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.